logo conference-reports

Kongressrapporter

Educational funding by logo MSD Oncology

ELCC 2019 - In first-line nonsquamous NSCLC, patients with EGFR mutations benefit from adding atezolizumab to standard care

Exploratory subgroup analysis of IMpower150 trial indicates efficacy for EGFR-mt+ patients given atezolizumab in addition to bevacizumab and standard chemotherapy
Tjenesten du prøver å få tilgang til er bare tilgjengelig for registrerte brukere. For å fortsette vennligst logg inn eller registrer deg for en gratis konto på Univadis